Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Intellia Therapeutics (NTLA) over the last 6 years, with Q3 2025 value amounting to $110.2 million.

  • Intellia Therapeutics' Shares Outstanding (Diluted Average) rose 909.49% to $110.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.2 million, marking a year-over-year increase of 909.49%. This contributed to the annual value of $98.8 million for FY2024, which is 1135.41% up from last year.
  • As of Q3 2025, Intellia Therapeutics' Shares Outstanding (Diluted Average) stood at $110.2 million, which was up 909.49% from $103.7 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $110.2 million for Q3 2025, and its period low was $68.2 million during Q2 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $87.7 million, with a median of $88.4 million in 2023.
  • Per our database at Business Quant, Intellia Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 2662.58% in 2021 and then surged by 317.61% in 2022.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Shares Outstanding (Diluted Average) stood at $70.9 million in 2021, then grew by 8.57% to $77.0 million in 2022, then grew by 15.33% to $88.8 million in 2023, then rose by 11.35% to $98.8 million in 2024, then rose by 11.47% to $110.2 million in 2025.
  • Its last three reported values are $110.2 million in Q3 2025, $103.7 million for Q2 2025, and $103.5 million during Q1 2025.